Leukotriene receptor antagonists for allergic rhinitis: A systematic review and meta-analysis

American Journal of Medicine

Volumn 116, Issue 5, 2004, Pages 338-344

  Wilson, Andrew M ^a   O'Byrne, Paul M ^a   Parameswaran, Krishnan ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CETIRIZINE; CINALUKAST; CORTICOSTEROID; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MOMETASONE FUROATE; MONTELUKAST; PLACEBO; POMILUKAST; PRANLUKAST; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ALLERGIC RHINITIS; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; META ANALYSIS; NOSE POLYP; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHINOCONJUNCTIVITIS; TREATMENT OUTCOME;

EID: 1242270608     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.10.030     Document Type: Review

References (44)

1. Settipane R.A. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc. 22:2001;185-189.
2. Meltzer E.O. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol. 108:(suppl):2001;S45-S53.
3. Radenne F., Lamblin C., Vandezande L.M., et al. Quality of life in nasal polyposis. J Allergy Clin Immunol. 104:1999;79-84.
4. Wasserman B. Allergic rhinitis and wellness opportunities. Manag Care Interface. 14:2001;38-45.
5. Law A.W., Reed S.D., Sundy J.S., Schulman K.A. Direct costs of allergic rhinitis in the United States estimates from the 1996 medical expenditure panel survey . J Allergy Clin Immunol. 111:2003;296-300.
6. Fineman S.M. The burden of allergic rhinitis beyond dollars and cents . Ann Allergy Asthma Immunol. 88:2002;2-7.
7. Grupp-Phelan J., Lozano P., Fishman P. Health care utilization and cost in children with asthma and selected comorbidities. J Asthma. 38:2001;363-373.
8. Wenzel S.E., Larsen G.L., Johnston K., et al. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis. 142:1990;112-119.
9. Pavord I.D., Ward R., Woltmann G., et al. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med. 160:1999;1905-1909.
10. Broide D.H., Eisman S., Ramsdell J.W., et al. Airway levels of mast cell-derived mediators in exercise-induced asthma. Am Rev Respir Dis. 141:1990;563-568.
11. Macfarlane A.J., Dworski R., Sheller J.R., et al. Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. Am J Respir Crit Care Med. 161:2000;1553-1558.
12. Busse W., Raphael G.D., Galant S., et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma a randomized clinical trial . J Allergy Clin Immunol. 107:2001;461-468.
13. Shaw R.J., Fitzharris P., Cromwell O., et al. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy. 40:1985;1-6.
14. Kowalski M.L., Sliwinska-Kowalska M., Igarashi Y., et al. Nasal secretions in response to acetylsalicylic acid. J Allergy Clin Immunol. 91:1993;580-598.
15. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials is blinding necessary? Control Clin Trials. 17:1996;1-12.
16. Pullerits T., Praks L., Skoogh B.E., et al. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med. 159:1999;1814-1818.
17. Wilson A.M., Sims E.J., Orr L.C., et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 87:2001;344-349.
18. Wilson A.M., Orr L.C., Sims E.J., et al. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy. 31:2001;61-68.
19. Wilson A.M., Dempsey O.J., Sims E.J., Lipworth B.J. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy. 31:2001;616-624.
20. Wilson A., Dempsey O.J., Sims E.J., et al. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy. 30:2000;833-838.
21. Wilson A.M., Orr L.C., Coutie W.J., et al. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy. 32:2002;126-132.
22. Juniper E.F., Guyatt G.H. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 21:1991;77-83.
23. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 7:1986;177-188.
24. Meltzer E.O., Malmstrom K., Lu S., et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis a randomized, placebo-controlled clinical trial . J Allergy Clin Immunol. 105:2000;917-922.
25. Nayak A.S., Philip G., Lu S., et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall . Ann Allergy Asthma Immunol. 88:2002;592-600.
26. Philip G., Malmstrom K., Hampel F.C., et al. Montelukast for treating seasonal allergic rhinitis a randomized, double-blind, placebo-controlled trial performed in the spring . Clin Exp Allergy. 32:2002;1020-1028.
27. Pullerits T., Praks L., Ristioja V., Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 109:2002;949-955.
28. van Adelsberg J., Philip G., LaForce C.F., et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 90:2003;214-222.
29. Di Rienzo L., Artuso A., Cerqua N. Antileukotrienes in the prevention of postoperative recurrence of nasal polyposis in ASA syndrome. [in Italian] Acta Otorhinolaryngol Ital. 20:2000;336-342.
30. Grundman T., Topfner M. Treatment of ASS-associated Polyposis (ASSAP) with a cysteinyl leukotriene receptor antagonist - a prospective drug study on its anti-inflammatory effects. Laryngorhinootologie. 80:2001;576-582.
31. Parnes S.M., Chuma A.V. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J. 79:2000;15-18.
32. Ragab S., Parikh A., Darby Y.C., Scadding G.K. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy. 31:2001;1385-1391.
33. Wilson A.M., White P.S., Gardiner Q., et al. Effects of leukotriene receptor antagonist therapy in patients with chronic rhinosinusitis in a real life rhinology clinic setting. Rhinology. 39:2001;142-146.
34. Malerba M., Radaeli A., Ceriani L., et al. Comparison of oral montelukast and inhaled fluticasone in the treatment of asthma associated with chronic rhinopolyposis a single blind randomised pilot study . Curr Ther Res Clin Exp. 63:2002;355-365.
35. Narita S., Kurose M., Obayashi K. Pranlukast produces beneficial effects in nasal symptoms on patients with perennial allergic rhinitis when used in combination with an antihistamine. [in Japanese] Practica Otologica. 94:2001;1131-1138.
36. Numata T., Konno A., Yamakoshi T., et al. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol. 108:1999;467-473.
37. Egger M., Zellweger-Zahner T., Schneider M., et al. Language bias in randomised controlled trials published in English and German. Lancet. 350:1997;326-329.
38. Cook D.J., Guyatt G.H., Ryan G., et al. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA. 269:1993;2749-2753.
39. Juniper E.F., Guyatt G.H., Griffith L.E., Ferrie P.J. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 98:1996;843-845.
40. Petitti DB. Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. New York, New York: Oxford University Press; 1994:90-114. Statistical Methods in Meta-Analysis.
41. Meltzer E.O., Weiler J.M., Widlitz M.D. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol. 97:1996;617-626.
42. Meltzer E.O. Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. Ann Allergy Asthma Immunol. 88:2002;23-29.
43. Mygind N., Dahl R., Bisgaard H. Leukotrienes, leukotriene receptor antagonists, and rhinitis. Allergy. 55:2000;421-424.
44. Nathan R.A. Pharmacotherapy for allergic rhinitis a critical review of leukotriene receptor antagonists compared with other treatments . Ann Allergy Asthma Immunol. 90:2003;182-190.